90. Retinitis pigmentosa Clinical trials / Disease details
Clinical trials : 130 / Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04794101 (ClinicalTrials.gov) | March 16, 2021 | 15/12/2020 | Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | Follow-up Phase 3 Randomized, Controlled Study of AAV5-RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene | X-Linked Retinitis Pigmentosa | Biological: Genetic: AAV5-RPGR 4e11;Biological: Genetic: AAV5-RPGR 2e11 | MeiraGTx UK II Ltd | Janssen Research & Development, LLC | Recruiting | 3 Years | N/A | All | 66 | Phase 3 | United States |